Q-omics provides the consensus-scored CIBAR1 profile across patient tissues and cancer cell-line models. CIBAR1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CIBAR1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CIBAR1 RNA expression shows 19,842 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where CIBAR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIBAR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIBAR1 survival associations across molecular data types. CIBAR1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIBAR1 RNA expression–survival associations across cancer types. High CIBAR1 expression shows unfavorable associations in MESO, UVM, HNSC, ACC and SARC, but favorable associations in READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CIBAR1 RNA expression.
This table summarizes CIBAR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CIBAR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIBAR1 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in HNSC, COAD and READ. The HNSC box plot shows higher CIBAR1 RNA expression in tumor versus normal tissue (log2 FC = +1.069, t-test p < 0.001).
This table shows molecular features associated with CIBAR1 in patient tissues and cancer cell lines. In patient samples, CIBAR1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CIBAR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
